Minakem Header W48

Minakem Header W48

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Quotient Sciences

Contact Supplier

Molecule to Cure. Fast.

Contact Supplier

Contact Supplier

Digital Content

Oxilio Signs a Significant Service Contract with Quotient Sciences to Support the Formulation Development of NXP-001

Details:

Quotient has prior experience of working with the Nuformix NXP-001 co-crystal and previously developed a capsule and a powder for oral suspension formulation of Aprepitant, evaluating its performance in a relative bioavailability study versus EMEND.

Lead Product(s): Aprepitant

Therapeutic Area: Gastroenterology Product Name: NXP-001

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Oxilio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 07, 2022

Quotient Company Banner

8th Winter Process Chemistry Conf.

Attending

envelop Contact Supplier

Tiziana Life Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

Details:

TZLS-401 (foralumab), the only entirely human anti-CD3 monoclonal antibody, shows reduced release of cytokines after IV administration in healthy volunteers and in patients with Crohn's disease.

Lead Product(s): Foralumab

Therapeutic Area: Gastroenterology Product Name: TZLS-401

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 25, 2022

ASK
US

Upload
your Pipeline Activity

Tiziana Life Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Tiziana Reports Phase 1 Clinical Data Demonstrating Oral Treatment with Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, is Well-tolerated in Healthy Volunteers

Details:

Foralumab (TZLS-401) encapsulated in an enteric-coated capsule, was well-tolerated at all doses tested and there were no drug-related safety issues even at the highest dose of 5 mg in this trial.

Lead Product(s): Foralumab

Therapeutic Area: Gastroenterology Product Name: TZLS-401

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY